Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Double-Blind Placebo-Controlled Dose Finding Study to Evaluate Safety/Efficacy of Ipamorelin Compared to Placebo for Recovery of Gastrointestinal Function in Patients Following Small or Large Bowel Resection w/Primary Anastomosis

NCT01280344 is registered in ClinicalTrials.gov with Helsinn Therapeutics (U.S.), Inc as lead sponsor.

NCT NCT01280344
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01280344 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Double-Blind Placebo-Controlled Dose Finding Study to Evaluate Safety/Efficacy of Ipamorelin Compared to Placebo for Recovery of Gastrointestinal Function in Patients Following Small or Large Bowel Resection w/Primary Anastomosis
Lead sponsor
Helsinn Therapeutics (U.S.), Inc
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2011
Completion date
May 31, 2014
Enrollment
320 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal dysmotility